Sign In
Buy CYDY
$0.276
-0.0143 (-4.93%)
At Close: Jun 03, 2026
Wall Street starts on back foot
10:03am, Monday, 19'th Jul 2021
10am: Proactive North America headlines: Todos Medical Ltd (OTCQB:TOMDF) to launch cPass SARS-CoV-2 neutralizing antibody detection kit Logiq Inc (NEO:LGIQ) (OTCQX:LGIQ) promotes Steven Hartman to chi
CytoDyn says it has strong preliminary results from 30 metastatic triple-negative breast cancer patients treated with leronlimab
08:05am, Monday, 19'th Jul 2021
CytoDyn Inc (OTCQB:CYDY) has shared strong preliminary results from its Phase 1b/2 trials and compassionate use study of its flagship drug candidate leronlimab in 30 metastatic triple-negative breast
CytoDyn will seek FDA guidance on proceeding with an expedited regulatory plan for approval of leronlimab with existing FDA Fast Track designation for mTNBC CytoDyn will seek FDA guidance on proceedin
CytoDyn advances to Phase 2 trial with leronlimab for mTNBC metastatic breast cancer treatment
07:36am, Monday, 12'th Jul 2021
CytoDyn Inc (OTCQB:CYDY) has announced that a clinical trial for its flagship drug candidate, leronlimab, has advanced from Phase 1b to a Phase 2 study. The leronlimab trial is being carried out in co
CytoDyn anticipates preliminary efficacy data regarding potential responders in metastatic triple-negative breast cancer in approximately two weeks
CytoDyn granted important US patent for methods of treating coronavirus infection with leronlimab
08:06am, Tuesday, 06'th Jul 2021
CytoDyn Inc (OTCQB:CYDY) has announced that its flagship drug candidate, leronlimab, has been granted US Patent No. 11,045,546 by the US Patent and Trademark Office (USPTO) for methods of treating cor
CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab
06:00am, Tuesday, 06'th Jul 2021
VANCOUVER, Washington, July 06, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the
CytoDyn submits dose justification report on Vyrologix for HIV to the US Food & Drug Administration
08:12am, Friday, 02'nd Jul 2021
CytoDyn Inc (OTCQB:CYDY) announced that it has submitted a dose justification report on its Vyrologix (leronlimab-PRO 140) drug to the US Food and Drug Administration (FDA), which will be followed by
CytoDyn submits dose justification report on on Vyrologix for HIV to the US Food & Drug Administration
08:08am, Friday, 02'nd Jul 2021
CytoDyn Inc (OTCQB:CYDY) announced that it has submitted a dose justification report on its Vyrologix (leronlimab-PRO 140) drug to the US Food and Drug Administration (FDA), which will be followed by
CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV
06:07pm, Thursday, 01'st Jul 2021
Management works to advance its BLA filing seeking FDA approval for leronlimab as a combination therapy for HIV patients while continuing its evaluation of other potential indications
NEW YORK--(BUSINESS WIRE)--A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) today announced that it has sent a notice to CY
CytoDyn pleased with preliminary results from long-haulers coronavirus trial
10:09am, Monday, 21'st Jun 2021
CytoDyn Inc (OTCQB:CYDY) has announced encouraging early data from its long-hauler CD15 trial, which aimed to assess leronlimab administered as a weekly injection in people experiencing COVID-19 (coro
CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments
04:01pm, Wednesday, 16'th Jun 2021
VANCOUVER, Washington, June 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist wit
SHAREHOLDER ALERT: CytoDyn Inc. (CYDY) Officers and Directors Under Investigation for Possible False Statements and Insider Trading
09:30am, Thursday, 10'th Jun 2021
SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of CytoDyn Inc. (OTC: CYDY) relating to possible fals
What's Behind This Wild-Card Coronavirus Stock?
06:15am, Tuesday, 08'th Jun 2021
Failure is not an option for this small-cap biotech developing a COVID-19 treatment.
